Global Anemia Therapeutics Market 2017-2021

Overview of the global anemia therapeutics market

Research analysis on the global anemia therapeutics market identifies that the new drug approvals for the treatment of various types of anemia or rare blood disorders will be one of the major factors that will have a positive impact on the growth of the market. The use of endari (L-glutamine oral powder) for the treatment of sickle cell disease in patients, aged five years and above, was approved by the US food and drug administration (FDA) in July 2017. Sickle cell disease is a rare blood disorder, which requires lifelong treatment. In addition, the government is supporting the manufacturer of endari, Emmaus, to facilitate research and developmental activities in the rare disease area. The granting of the orphan drug designation enabled them to earn financial incentives, market exclusivity, and shorter review periods. Similarly, the erythropoiesis-stimulating agent (ESA) called peginesatide for the treatment of anemia in CKD-affected patients undergoing dialysis or kidney anemia was also approved by the US FDA in March 2012. Technavio’s market research analysts predict that this market will grow at a CAGR of close to 9% by 2021.

The low level of oxygen in the body can cause a condition called hypoxia. As a result, researchers are focusing on the development of hypoxia-inducible factor (HIF) stabilizers for the treatment of anemia associated with chronic kidney disease (CKD). For instance, FibroGen's FG-2216 AND FG-4592 are anemia therapeutics for anemia treatment that leads to increased stability of HIF-2 alpha in the kidney by inhibiting the HIF prolyl hydroxylase. According to this research analysis, the development of HIF stabilizers will be one of the key trends that will gain traction in the anemia therapeutics market during the projected period.

Competitive landscape and key vendors

The anemia therapeutics market is characterized by the presence of many large and small vendors. These vendors are increasingly competing against each other based on factors such as aggressive pricing, novel therapeutics, and advancements in technology. Vendors in the anemia drugs market are also focusing on expanding their geographical reach by increasing their investments in the research and developmental activities.

Key vendors in this market are -

• AMAG Pharmaceuticals
• Daiichi Sankyo
• Galenica
• Pharmacosmos

Other prominent vendors in the market include Acceleron Pharma, Bayer, GlycoMimetics, GlaxoSmithKline, Novartis, Pieris Pharmaceuticals, and Sanofi.

Segmentation by disease type and analysis of the anemia therapeutics market

• Iron deficiency anemia
• Sickle cell anemia
• Pernicious anemia
• Hemolytic anemia

The iron deficiency anemia market segment accounted for the major shares of the anemia drugs market during 2016. The prevalence of iron deficiency anemia is increasing in the developing as well as developed countries. Also, around 5% women and 2% men in America are affected by the iron deficiency anemia as per the National Institutes of Health (NIH). The low bioavailability of iron in the diet in developing countries and poor iron absorption and blood loss in developed countries are the main causes of iron deficiency anemia. This drives the need for oral iron therapeutics as the first-line therapy.

Segmentation by geography and analysis of the anemia therapeutics market

• Americas
• APAC
• EMEA

It has been observed that the incidence of various types of anemia is increasing in the Americas. This is compelling vendors such as Daiichi Sankyo to focus on the development of intravenous anemia therapeutics. The increasing demand for a ferric carboxymaltose iron solution for iron deficiency anaemia will boost the adoption of CKD and anemia therapeutics in the Americas during the next four years. The Americas will be the major contributor to the anemia therapeutics market throughout the next few years.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global anemia therapeutics market?
• What are the key market trends impacting the growth of the global anemia therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the global anemia therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global anemia therapeutics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global anemia therapeutics market?

Technavio also offers customization on reports based on specific client requirement